¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antineuronal antibody, type 2"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hypertrophic type
    ºñ´ëÇü
  • hebephrenic type schizophrenia
    ÆÄ°úÇüÁ¤½ÅºÐ¿­º´
  • hemispheric type
    ¹Ý±¸Çü
  • hemochorial type
    À¶Ç÷¸ðÇü
  • introversion type
    ³»ÇâÇü
  • intuitive type
    Á÷°üÇü
  • linear type constitution
    ¼±ÇüüÇü
  • mating type
    ±³¹èÇü
  • meromyarian type
    ºÎºÐ±ÙÀ°Çü
  • nomenclatural type
    ºÐ·ùÇÐÀû±âÁظí
  • organic reaction type
    ±âÁú¹ÝÀÀÇü
  • ovulatory type
    ¹è¶õÇü
  • polymyarian type
    ´Ù±ÙÀ°Çü
  • precision type attachment
    Á¤¹ÐÇüºÎÂø
  • propagative type
    Áõ½ÄÇü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antinuclear antibody
    Ç×ÇÙÇ×ü
  • antiphospholipid antibody
    Ç×ÀÎÁöÁúÇ×ü
  • antisperm antibody
    Ç×Á¤ÀÚÇ×ü
  • atypical antibody
    ºñÁ¤ÇüÇ×ü
  • autoimmune antibody
    ÀÚ°¡¸é¿ªÇ×ü
  • blocking antibody
    Â÷´ÜÇ×ü
  • polyclonal antibody
    ´ÙŬ·ÐÇ×ü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody titer
    Ç×ü°¡
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • disorganized type schizophrenia
    ºØ±«Á¤½ÅºÐ¿­º´
  • dromedary type
    ´ÜºÀÇü
  • dysplastic type
    Çü¼ºÀÌ»óÇü
  • expansive type
    °ú´ëÇü
  • extroverted type
    ¿ÜÇâÇü
  • extroverted feeling type
    ¿ÜÇâÀû°¨Á¤Çü
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • hebephrenic type schizophrenia
    ÆÄ°úÁ¤½ÅºÐ¿­º´
  • hemispheric type
    ¹Ý±¸Çü
  • hemochorial type
    À¶Ç÷¸ðÇü
  • holomyarian type
    ¿ÏÀü±ÙÀ°Çü
  • hypertrophic type
    ºñ´ëÇü
  • tuberculin-type hypersensitivity
    (¢¡delayed-type hypersensitivity) Áö¿¬°ú¹Î
  • introversion type
    ³»ÇâÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Ogawa type
    ¿À°¡¿ÍÇü
  • RF coil type
    °íÁÖÆÄ ÄÚÀÏ À¯Çü
  • T-type channel
    T-Çü Åë·Î
  • aberrant type
    ÀÌÇü(ì¶úþ)
  • abortive type
    ºÎÀüÇü(ÝÕîïúþ).
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • agammaglobulinemia,x-linked, bruton type
    ¼º¿°»öü ¿¬°ü¼º, ºê·çÅæÇü(àõæøßäô÷ æáμàõ, ¡­úþ)
  • anovulatory type
    ¹«¹è¶õÇü
  • glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
  • golgi type i neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • golgi type ii neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • growth onset type diabetes
    Ãʱâ´ç´¢º´.
  • hebephrenic type
    ÆÄ°úÇü(÷òÍþúþ)
  • hemochorial type
    À¶Ç÷¸ðÇü(ëÖúìÙ¾úþ).
  • hemoglobin C type
    CÇü Ç÷»ö¼Ò
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • body type
    üÇü
  • body type
    üÇü(ô÷úþ).
  • bubble type vaporizer
    ±âÆ÷Çü ±âÈ­±â
  • calcified hypertrophic type
    ¼®È¸È­ºñ´ëÇü
  • catatonic type
    ±äÀåÇü
  • cellular type dermatofibroma
    ¼¼Æ÷Çü ÇǺμ¶À¯Á¾
  • chief cell type i glomus cell
    °ú¸³¼¼Æ÷
  • cryptogenic type
    ÀáÀçÇü(ËöËøÌ´).
  • cryptogenic type
    ÀáÀçÇü(íÖî¤úþ).
  • crystal type
    °áÁ¤Çü
  • culture, type
    Ç¥ÁرÕÁÖ, ±âÁØÁÖ
  • cyclicodevelopmental type
    ÁÖ±âÀû ¹ßÀ°Çü(ÊÙËÑËôÌ´).
  • cyclicopropagative type
    ÁÖ±âÀû Áõ½ÄÇü(ÊÙÌ¡ËàÌ´).
  • delayed type hypersensitivity
  • delayed-type hypersensitivity
    Áö¿¬Çü °ú¹Î¹ÝÀÀ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
    [¿¾ ¿ë¾î] ±¸Çüµ¿Á¤¸Æ¹®ÇÕ
  • Mixed type of artery
    È¥ÇÕÇüµ¿¸Æ
    [¿¾ ¿ë¾î] È¥ÇÕÇüµ¿¸Æ
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Pneumocyte type II
    °ú¸³ÇãÆÄ²Ê¸®¼¼Æ÷
    [¿¾ ¿ë¾î] ´ëÆóÆ÷¼¼Æ÷
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ÀåÃà»è´Ù±Ø½Å°æ¿ø
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Hypertrophic type
    ºñ´ëÇü
    [¿¾ ¿ë¾î] ºñ´ëÇü
  • Fibrous type of vein
    ¼¶À¯ÇüÁ¤¸Æ
    [¿¾ ¿ë¾î] ¼¶À¯ÇüÁ¤¸Æ
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ´ÜÃà»è´Ù±Ø½Å°æ¿ø
  • Pneumocyte type I
    È£ÈíÇãÆÄ²Ê¸®¼¼Æ÷
    [¿¾ ¿ë¾î] È£Èí»óÇǼ¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • type C virus
    CÇü(úþ) ¹ÙÀÌ·¯½º
  • type C RNA virus
    CÇü(úþ) RNA ¹ÙÀÌ·¯½º
  • type I error
    IÇü(úþ) ¿ÀÂ÷(è¦ó¬)
  • type II error
    IIÇü(úþ) ¿ÀÂ÷(è¦ó¬)
  • type I immunoglobulin
    IÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type II immunoglobulin
    IIÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type K immunoglobulin
    KÇü(úþ) ¸é¿ª(Øóæ¹) ±Û·ÎºÒ¸°
  • type L immunoglobulin
    LÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type-specific antigen
    ÇüƯÀÌ Ç׿ø(úþ÷åì¶ù÷ê«)
  • Watson-Crick-type DNA
    ¿Ó½¼-Å©¸¯Çü(úþ) DNA
  • wild-type
    ¾ß»ýÇü(å¯ßæúþ)
  • wild-type allele
    ¾ß»ýÇü(å¯ßæúþ) ´ë¸³(Óߨ¡)À¯ÀüÀÚ(ë¶îîí­)
  • wild-type gene
    ¾ß»ýÇü(å¯ßæúþ) À¯ÀüÀÚ(ë¶îîí­)
  • acquired antibody
    "ȹµæÇ×ü (üòÔðù÷ô÷), ÈÄõ¼ºÇ×ü (ý­ô¸àõù÷ô÷)"
  • agglutinating antibody
    ÀÀÁýÇ×ü(ëêó¢ù÷ô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ALL Acute Lymphocytic Leukemia
  ÇüÅÂÇÐÀû ºÐ·ù
    L1; Small, Homogenous(...
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
AMA against medical advice; alkaline membrane assay; American Management Association; American Medical A...
NA Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida...
NF Neuro-Fibromatosis
  = Von Recklinghausen's Disease
  NF 1; Neuro-Fibroma...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NAb 1-neutralizing-antibody
AChR-AB Acetylcholine Receptor Antibody
APA Anti phospholipid antibody
ANCA Anti-Neutrophil Cytoplasmic Antibody
ACA Anti-cardiolipin antibody
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen antibody complex
    Ç׿ø Ç×ü º¹ÇÕü
    Ç׿ø°ú Ç×ü°¡ °áÇÕÇÑ °Í. ¸é¿ª º¹ÇÕü¶ó°íµµ ÇÑ´Ù. Ç×ü´Â Ç׿ø°ú °áÇÕÇÏ¿© º¹ÇÕü¸¦ ¸¸µé¸é º¸Ã¼ Ȱ¼ºÈ­ ÀÛ¿ëÀ» °¡Áö°Ô µÈ´Ù. ±×·¡¼­ »ýü ³»¿¡¼­ ¸é¿ª º¹ÇÕü°¡ Çü¼ºµÇ¸é ±× ÁÖº¯¿¡¼­ ºÎü°¡ Ȱ¼ºÈ­µÇ¾î ¿°Áõ¹ÝÀÀÀ» ¹ß»ý½ÃŰ´Â ¼ÀÀÌ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â ħ°­¼ºÀÇ °ÍÀ¸·Î µÇ±â ½±´Ù. µû¶ó¼­ Ç׿øÀÇ Ä§ÀÔ ºÎÀ§¿¡ ¿°Áõ¹ÝÀÀÀÌ »ý±â±â ½±´Ù.
  • antigen antibody reaction
    Ç׿ø Ç×ü ¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿ø-Ç×ü ¹ÝÀÀ
  • antiglobulin antibody
    Çױ۷κθ° Ç×ü
  • antiinsulin antibody
    Ç×Àν¶¸° Ç×ü
  • antinuclear antibody
    Ç×ÇÙ Ç×ü
    ÇÙ Ç׿ø¿¡ ´ëÇÑ Ç×ü·Î¼­ º¸Åë Àü½Å¼º È«¹Ý¼º ³¶Ã¢À» °¡Áø ȯÀÚÀÇ Ç÷û¿¡¼­ ¹ß°ßµÈ´Ù. ±×·¯³ª ·ù¸¶Æ¼¼º °üÀý¿°, °øÇÇÁõ ±×¸®°í ´Ù¸¥ °áÇÕÁ¶Á÷Àå¾Ö ȯÀÚ¿¡¼­µµ ¹ß°ßµÈ´Ù.
  • antiphospholipid antibody
    Ç×ÀÎÁöÁú Ç×ü
  • antiplatelet antibody
    Ç×Ç÷¼ÒÆÇ Ç×ü
  • blocking antibody
    Â÷´Ü Ç×ü
    µ¿ÀǾî=blocker.
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
  • cellular antibody
    ¼¼Æ÷ Ç×ü
    ƯÀÌÀûÀÎ ¾Æ¹Ì³ë»ê ¹è¿­À» °¡Áø ¼¼Æ÷¼º ¸é¿ª ±Û·ÎºÒ¸° ºÐÀÚ.
  • circulating antibasement membrane antibody
    ¼øÈ¯ Ç×±âÀú¸· Ç×ü
  • cold reacting antibody
    ÇÑ·© Ç×ü
  • complement fixing antibody
    º¸Ã¼ °áÇÕ Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
antibody excess In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present.
(05 Mar 2000)
antibody-forming cell <immunology> B-cells (plasma cells) that are dedicated to producing secreted antibodies.
(09 Feb 1998)
antibody induced lysis <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis.
See: complement lysis, natural killer cells.
(09 Feb 1998)
antibody producing cell <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell.
(18 Nov 1997)
antibody-producing cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise.
(12 Dec 1998)
antibody specificity The property of antibodies which enables them to react with some antigenic determinants and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
(12 Dec 1998)
antibody technology <molecular biology> Techniques for the synthesis of polyclonal and monoclonal antibodies for use in research, diagnostics and therapeutics.
(09 Feb 1998)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
anti-idiotype antibody <immunology> An antibody directed against the antigen specific part of the sequence of an antibody or T-cell receptor and thus recognise the binding sites of other antibodies.
In principle an anti-idiotype antibody should inhibit a specific immune response and they are important to the regulation of the immune system.
(13 Nov 1997)
anti-insulin antibody A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result.
(27 Sep 1997)
antinuclear antibody <immunology> Antinuclear antibody is an antibody that react against components of the cell nucleus such as DNA, RNA, histone or non-histone proteins.
These antibodies are present in a variety of immunologic or autoimmune diseases including systemic lupus erythematosus, systemic sclerosis, scleroderma, Sjogren's syndrome, rheumatoid arthritis, polymyositis, dermatomyositis and in persons taking hydralazine, procainamide or isoniazid.
A serologic measurement for antinuclear antibodies can aid in the diagnosis of unexplained arthritis, rashes or chest pains.
Acronym: ANA
(12 Jan 1998)
anti-P antibody <haematology, investigation> A serologic blood test used to detect the Donath-landsteiner antibody in serum.
This test is performed in cases of suspected paroxysmal cold haemoglobinuria. A normal result is indicated by an absence of antibodies. The antibody is directed toward the P-antigen complex which is located on the surface of red blood cells. In some way, cold temperatures trigger the antibody to bind to this site.
(13 Jan 1998)
antiparietal cell antibody <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells.
Less than 2% of the general population will be antibody positive although this can be higher in the elderly.
Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes.
(13 Jan 1998)
antiphospholipid antibody <immunology, syndrome> An uncommon disorder that is characterised by hypercoagulability due to the presence of antibodies against phospholipids.
These patients exhibit a tendency for recurrent and life-threatening thrombosis and embolic events (for example stroke). Individuals with antiphospholipid syndrome also have an increased tendency toward deep venous thrombosis, myocardial infarction and spontaneous abortions in females.
Antiphospholipid syndrome may be seen by itself or in association with other autoimmune illnesses (for example lupus) or with some infections.
Treatment includes long-term heparin and warfarin.
(13 Jan 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ideal type
    ÀÌ»óÇü
  • italic type
    (ÀÎ)ÀÌÅÚ¸¯Ã¼;»çü
  • moon type
    (¸ÍÀοëÀÇ)¹®½Ä¼±ÀÚ
  • repulsive(-type) maglev
    ¹Ý¹ß½Ä Àڱ⠺λó(Â÷ü¸¦ ¶ß°ÔÇϱâ À§ÇØ ÀüÀÚ¼®ÀÇ ¹Ý¹ß·ÂÀ» ÀÌ¿ë)
  • type
    Çü;À¯Çü;¾ç½Ä;ÀüÇü;°ßº»;Ç¥;ȰÀÚ;Ç÷¾×Çü;in ~ ȰÀڷΠ§(Â¥¼­);set ~ Á¶ÆÇÇÏ´Ù
  • type
    ŸÀÌÇÁ¶óÀÌÅÍ·Î Âï´Ù;(Ç÷¾×)ÇüÀ» °Ë»çÇÏ´Ù;»ó¡ÇÏ´Ù;...ÀÇ ÀüÇüÀÌ µÇ´Ù
  • type cast
    (±ØÁß Àι°ÀÇ ½ÅÀå,¸ñ¼Ò¸® µûÀ§¿¡ ¸Â´Â) ¹è¿ì¸¦ ¹è¿ªÇÏ´Ù
  • type founder
    ȰÀÚ ÁÖÁ¶°ø(¾÷ÀÚ)
  • type metal
    ȰÀÚ ÇÕ±Ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á